nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—Benzyl alcohol—ALDH2—esophageal cancer	0.0147	0.253	CrCbGaD
Dextroamphetamine—Lacosamide—CA1—esophageal cancer	0.0112	0.192	CrCbGaD
Dextroamphetamine—Lacosamide—CA2—esophageal cancer	0.00847	0.145	CrCbGaD
Dextroamphetamine—Tranylcypromine—CYP2A6—esophageal cancer	0.00738	0.127	CrCbGaD
Dextroamphetamine—Sudden death—Capecitabine—esophageal cancer	0.00658	0.0391	CcSEcCtD
Dextroamphetamine—Cardiomyopathy—Capecitabine—esophageal cancer	0.00658	0.0391	CcSEcCtD
Dextroamphetamine—Selegiline—CYP2A6—esophageal cancer	0.00572	0.0982	CrCbGaD
Dextroamphetamine—Infection—Carboplatin—esophageal cancer	0.00552	0.0328	CcSEcCtD
Dextroamphetamine—Sudden death—Methotrexate—esophageal cancer	0.0049	0.0291	CcSEcCtD
Dextroamphetamine—Amphetamine—CYP2A6—esophageal cancer	0.00475	0.0816	CrCbGaD
Dextroamphetamine—Body temperature increased—Carboplatin—esophageal cancer	0.00439	0.0261	CcSEcCtD
Dextroamphetamine—Nateglinide—PTGS1—esophageal cancer	0.00392	0.0672	CrCbGaD
Dextroamphetamine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00339	0.0201	CcSEcCtD
Dextroamphetamine—Blood pressure increased—Capecitabine—esophageal cancer	0.00337	0.02	CcSEcCtD
Dextroamphetamine—Irritability—Cisplatin—esophageal cancer	0.00317	0.0188	CcSEcCtD
Dextroamphetamine—Speech disorder—Methotrexate—esophageal cancer	0.00292	0.0173	CcSEcCtD
Dextroamphetamine—Libido decreased—Capecitabine—esophageal cancer	0.00264	0.0157	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00252	0.015	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Cisplatin—esophageal cancer	0.00251	0.0149	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.0025	0.0148	CcSEcCtD
Dextroamphetamine—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00243	0.0144	CcSEcCtD
Dextroamphetamine—Irritability—Capecitabine—esophageal cancer	0.00233	0.0139	CcSEcCtD
Dextroamphetamine—Mood swings—Capecitabine—esophageal cancer	0.00232	0.0138	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Capecitabine—esophageal cancer	0.00223	0.0133	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.0022	0.0131	CcSEcCtD
Dextroamphetamine—Selegiline—ABCB1—esophageal cancer	0.00213	0.0366	CrCbGaD
Dextroamphetamine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00193	0.0115	CcSEcCtD
Dextroamphetamine—Weight decreased—Capecitabine—esophageal cancer	0.00191	0.0113	CcSEcCtD
Dextroamphetamine—Depression—Capecitabine—esophageal cancer	0.00188	0.0112	CcSEcCtD
Dextroamphetamine—Tremor—Cisplatin—esophageal cancer	0.00187	0.0111	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00187	0.0111	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00186	0.011	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00186	0.011	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Capecitabine—esophageal cancer	0.00185	0.011	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Capecitabine—esophageal cancer	0.00183	0.0109	CcSEcCtD
Dextroamphetamine—Irritability—Methotrexate—esophageal cancer	0.00174	0.0103	CcSEcCtD
Dextroamphetamine—Convulsion—Cisplatin—esophageal cancer	0.00173	0.0103	CcSEcCtD
Dextroamphetamine—Mood swings—Methotrexate—esophageal cancer	0.00172	0.0102	CcSEcCtD
Dextroamphetamine—Anxiety—Cisplatin—esophageal cancer	0.0017	0.0101	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00164	0.00973	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00163	0.00968	CcSEcCtD
Dextroamphetamine—Infection—Cisplatin—esophageal cancer	0.00162	0.00961	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Capecitabine—esophageal cancer	0.0016	0.00949	CcSEcCtD
Dextroamphetamine—Tachycardia—Cisplatin—esophageal cancer	0.00159	0.00945	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00158	0.00936	CcSEcCtD
Dextroamphetamine—Anorexia—Cisplatin—esophageal cancer	0.00155	0.00922	CcSEcCtD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.00149	0.00193	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00147	0.00191	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP26A1—esophageal cancer	0.00147	0.0019	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ELMO1—esophageal cancer	0.00147	0.0019	CbGpPWpGaD
Dextroamphetamine—Dyspnoea—Cisplatin—esophageal cancer	0.00145	0.00863	CcSEcCtD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00145	0.00188	CbGpPWpGaD
Dextroamphetamine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00145	0.0086	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—AKAP13—esophageal cancer	0.00144	0.00186	CbGpPWpGaD
Dextroamphetamine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00144	0.00852	CcSEcCtD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.00144	0.00186	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—GHRL—esophageal cancer	0.00143	0.00184	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Cisplatin—esophageal cancer	0.00142	0.00841	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00141	0.00836	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00141	0.00182	CbGpPWpGaD
Dextroamphetamine—Depression—Methotrexate—esophageal cancer	0.0014	0.0083	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00139	0.00826	CcSEcCtD
Dextroamphetamine—Tremor—Capecitabine—esophageal cancer	0.00138	0.00819	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTO1—esophageal cancer	0.00137	0.00177	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTO1—esophageal cancer	0.00135	0.00174	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00135	0.00174	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00135	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—esophageal cancer	0.00135	0.00174	CbGpPWpGaD
Dextroamphetamine—Sweating—Methotrexate—esophageal cancer	0.00135	0.00798	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00133	0.00171	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PDE4D—esophageal cancer	0.00131	0.0017	CbGpPWpGaD
Dextroamphetamine—Palpitations—Capecitabine—esophageal cancer	0.0013	0.00772	CcSEcCtD
Dextroamphetamine—Body temperature increased—Cisplatin—esophageal cancer	0.00129	0.00765	CcSEcCtD
Dextroamphetamine—ADRA1B—AMPK Signaling—CDKN1A—esophageal cancer	0.00128	0.00166	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—esophageal cancer	0.00128	0.00165	CbGpPWpGaD
Dextroamphetamine—Hypertension—Capecitabine—esophageal cancer	0.00127	0.00755	CcSEcCtD
Dextroamphetamine—Chest pain—Capecitabine—esophageal cancer	0.00125	0.00744	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—GNG7—esophageal cancer	0.00125	0.00162	CbGpPWpGaD
Dextroamphetamine—Anxiety—Capecitabine—esophageal cancer	0.00125	0.00742	CcSEcCtD
Dextroamphetamine—Dry mouth—Capecitabine—esophageal cancer	0.00123	0.00728	CcSEcCtD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00121	0.00156	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Cisplatin—esophageal cancer	0.0012	0.00713	CcSEcCtD
Dextroamphetamine—Infection—Capecitabine—esophageal cancer	0.00119	0.00709	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Methotrexate—esophageal cancer	0.00119	0.00707	CcSEcCtD
Dextroamphetamine—Tachycardia—Capecitabine—esophageal cancer	0.00117	0.00696	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—XIAP—esophageal cancer	0.00117	0.00151	CbGpPWpGaD
Dextroamphetamine—Asthenia—Cisplatin—esophageal cancer	0.00117	0.00694	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Capecitabine—esophageal cancer	0.00116	0.0069	CcSEcCtD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00115	0.00149	CbGpPWpGaD
Dextroamphetamine—Anorexia—Capecitabine—esophageal cancer	0.00115	0.0068	CcSEcCtD
Dextroamphetamine—ADRA1A—AMPK Signaling—CDKN1A—esophageal cancer	0.00114	0.00148	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.00112	0.00145	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Cisplatin—esophageal cancer	0.00112	0.00662	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—ALDH2—esophageal cancer	0.00111	0.00144	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CTNNA1—esophageal cancer	0.00111	0.00143	CbGpPWpGaD
Dextroamphetamine—ADRA1B—LPA receptor mediated events—EGFR—esophageal cancer	0.00111	0.00143	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CXCL2—esophageal cancer	0.0011	0.00142	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.00109	0.00141	CbGpPWpGaD
Dextroamphetamine—Insomnia—Capecitabine—esophageal cancer	0.00109	0.00645	CcSEcCtD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—esophageal cancer	0.00107	0.00139	CbGpPWpGaD
Dextroamphetamine—Dyspnoea—Capecitabine—esophageal cancer	0.00107	0.00636	CcSEcCtD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.00106	0.00138	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTT1—esophageal cancer	0.00106	0.00137	CbGpPWpGaD
Dextroamphetamine—Dyspepsia—Capecitabine—esophageal cancer	0.00106	0.00628	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00105	0.00136	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP2A6—esophageal cancer	0.00105	0.00135	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00105	0.00135	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Capecitabine—esophageal cancer	0.00104	0.0062	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR ligand binding—GNG7—esophageal cancer	0.00104	0.00135	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00104	0.00616	CcSEcCtD
Dextroamphetamine—Vomiting—Cisplatin—esophageal cancer	0.00104	0.00615	CcSEcCtD
Dextroamphetamine—Fatigue—Capecitabine—esophageal cancer	0.00104	0.00615	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—PSME1—esophageal cancer	0.00103	0.00133	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PSME2—esophageal cancer	0.00103	0.00133	CbGpPWpGaD
Dextroamphetamine—Rash—Cisplatin—esophageal cancer	0.00103	0.0061	CcSEcCtD
Dextroamphetamine—Constipation—Capecitabine—esophageal cancer	0.00103	0.0061	CcSEcCtD
Dextroamphetamine—Dermatitis—Cisplatin—esophageal cancer	0.00103	0.0061	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—ANXA1—esophageal cancer	0.00102	0.00132	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00102	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ANXA1—esophageal cancer	0.000996	0.00129	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—SST—esophageal cancer	0.000996	0.00129	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—PTGS1—esophageal cancer	0.000993	0.00128	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000983	0.00583	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000971	0.00126	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—GHRL—esophageal cancer	0.000971	0.00126	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—SST—esophageal cancer	0.000969	0.00125	CbGpPWpGaD
Dextroamphetamine—Nausea—Cisplatin—esophageal cancer	0.000969	0.00575	CcSEcCtD
Dextroamphetamine—Urticaria—Capecitabine—esophageal cancer	0.000955	0.00567	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—FBXW7—esophageal cancer	0.000955	0.00123	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000955	0.00123	CbGpPWpGaD
Dextroamphetamine—Body temperature increased—Capecitabine—esophageal cancer	0.00095	0.00564	CcSEcCtD
Dextroamphetamine—Abdominal pain—Capecitabine—esophageal cancer	0.00095	0.00564	CcSEcCtD
Dextroamphetamine—Convulsion—Methotrexate—esophageal cancer	0.00095	0.00564	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000947	0.00123	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—GHRL—esophageal cancer	0.000945	0.00122	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.000934	0.00121	CbGpPWpGaD
Dextroamphetamine—Chest pain—Methotrexate—esophageal cancer	0.000933	0.00554	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000927	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—GNG7—esophageal cancer	0.000926	0.0012	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—CXCL2—esophageal cancer	0.000919	0.00119	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000909	0.00118	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—PIK3CA—esophageal cancer	0.000904	0.00117	CbGpPWpGaD
Dextroamphetamine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000895	0.00531	CcSEcCtD
Dextroamphetamine—Infection—Methotrexate—esophageal cancer	0.000889	0.00528	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Capecitabine—esophageal cancer	0.000886	0.00526	CcSEcCtD
Dextroamphetamine—ADRA1B—Signaling Pathways—GDI2—esophageal cancer	0.000875	0.00113	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—esophageal cancer	0.000875	0.00113	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NOTCH2—esophageal cancer	0.00087	0.00113	CbGpPWpGaD
Dextroamphetamine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000865	0.00513	CcSEcCtD
Dextroamphetamine—Asthenia—Capecitabine—esophageal cancer	0.000862	0.00512	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ANXA1—esophageal cancer	0.000854	0.0011	CbGpPWpGaD
Dextroamphetamine—Anorexia—Methotrexate—esophageal cancer	0.000853	0.00506	CcSEcCtD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ADCYAP1—esophageal cancer	0.000848	0.0011	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	0.000846	0.00109	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP1B1—esophageal cancer	0.000844	0.00109	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000833	0.00108	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—SST—esophageal cancer	0.000831	0.00107	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Capecitabine—esophageal cancer	0.000822	0.00488	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCR ligand binding—CXCL2—esophageal cancer	0.000816	0.00106	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—GHRL—esophageal cancer	0.00081	0.00105	CbGpPWpGaD
Dextroamphetamine—Insomnia—Methotrexate—esophageal cancer	0.000809	0.0048	CcSEcCtD
Dextroamphetamine—ADRA1A—AMPK Signaling—PIK3CA—esophageal cancer	0.000803	0.00104	CbGpPWpGaD
Dextroamphetamine—Dyspnoea—Methotrexate—esophageal cancer	0.000798	0.00473	CcSEcCtD
Dextroamphetamine—Somnolence—Methotrexate—esophageal cancer	0.000795	0.00472	CcSEcCtD
Dextroamphetamine—Dizziness—Capecitabine—esophageal cancer	0.000795	0.00472	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP19A1—esophageal cancer	0.000794	0.00103	CbGpPWpGaD
Dextroamphetamine—Dyspepsia—Methotrexate—esophageal cancer	0.000788	0.00467	CcSEcCtD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000783	0.00101	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Methotrexate—esophageal cancer	0.000778	0.00462	CcSEcCtD
Dextroamphetamine—ADRA1A—Signaling Pathways—GDI2—esophageal cancer	0.000777	0.00101	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—esophageal cancer	0.000777	0.001	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000773	0.00458	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000772	0.000999	CbGpPWpGaD
Dextroamphetamine—Fatigue—Methotrexate—esophageal cancer	0.000771	0.00458	CcSEcCtD
Dextroamphetamine—Vomiting—Capecitabine—esophageal cancer	0.000764	0.00454	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ANXA1—esophageal cancer	0.000759	0.000981	CbGpPWpGaD
Dextroamphetamine—Rash—Capecitabine—esophageal cancer	0.000758	0.0045	CcSEcCtD
Dextroamphetamine—Dermatitis—Capecitabine—esophageal cancer	0.000757	0.00449	CcSEcCtD
Dextroamphetamine—Headache—Capecitabine—esophageal cancer	0.000753	0.00447	CcSEcCtD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—PIK3CA—esophageal cancer	0.000751	0.000972	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—SST—esophageal cancer	0.000738	0.000955	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000732	0.00434	CcSEcCtD
Dextroamphetamine—TAAR1—Signaling Pathways—SMAD4—esophageal cancer	0.000731	0.000945	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—GHRL—esophageal cancer	0.000719	0.00093	CbGpPWpGaD
Dextroamphetamine—Nausea—Capecitabine—esophageal cancer	0.000714	0.00424	CcSEcCtD
Dextroamphetamine—Urticaria—Methotrexate—esophageal cancer	0.000711	0.00422	CcSEcCtD
Dextroamphetamine—Abdominal pain—Methotrexate—esophageal cancer	0.000707	0.0042	CcSEcCtD
Dextroamphetamine—Body temperature increased—Methotrexate—esophageal cancer	0.000707	0.0042	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKAP13—esophageal cancer	0.000678	0.000876	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Methotrexate—esophageal cancer	0.000659	0.00391	CcSEcCtD
Dextroamphetamine—Asthenia—Methotrexate—esophageal cancer	0.000642	0.00381	CcSEcCtD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000638	0.000824	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KMT2D—esophageal cancer	0.000633	0.000818	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PDE4D—esophageal cancer	0.00062	0.000801	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKAP13—esophageal cancer	0.000615	0.000796	CbGpPWpGaD
Dextroamphetamine—Diarrhoea—Methotrexate—esophageal cancer	0.000612	0.00363	CcSEcCtD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000612	0.000791	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000608	0.000786	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKAP13—esophageal cancer	0.000602	0.000778	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HIF1A—esophageal cancer	0.000598	0.000773	CbGpPWpGaD
Dextroamphetamine—Dizziness—Methotrexate—esophageal cancer	0.000592	0.00351	CcSEcCtD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GNG7—esophageal cancer	0.000589	0.000762	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KDR—esophageal cancer	0.000572	0.00074	CbGpPWpGaD
Dextroamphetamine—Vomiting—Methotrexate—esophageal cancer	0.000569	0.00338	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000565	0.00073	CbGpPWpGaD
Dextroamphetamine—Rash—Methotrexate—esophageal cancer	0.000564	0.00335	CcSEcCtD
Dextroamphetamine—ADRA1B—Signaling Pathways—ADCYAP1—esophageal cancer	0.000564	0.000729	CbGpPWpGaD
Dextroamphetamine—Dermatitis—Methotrexate—esophageal cancer	0.000564	0.00335	CcSEcCtD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PDE4D—esophageal cancer	0.000563	0.000728	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KMT2D—esophageal cancer	0.000562	0.000727	CbGpPWpGaD
Dextroamphetamine—Headache—Methotrexate—esophageal cancer	0.000561	0.00333	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PDE4D—esophageal cancer	0.00055	0.000712	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKAP13—esophageal cancer	0.000546	0.000707	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000542	0.000701	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NOTCH1—esophageal cancer	0.000539	0.000697	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GNG7—esophageal cancer	0.000535	0.000692	CbGpPWpGaD
Dextroamphetamine—Nausea—Methotrexate—esophageal cancer	0.000532	0.00315	CcSEcCtD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GNG7—esophageal cancer	0.000524	0.000677	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—CXCL2—esophageal cancer	0.000519	0.000672	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—WWOX—esophageal cancer	0.000516	0.000667	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ADCYAP1—esophageal cancer	0.000501	0.000648	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PDE4D—esophageal cancer	0.0005	0.000646	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FKBP1A—esophageal cancer	0.000491	0.000635	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CREBBP—esophageal cancer	0.000489	0.000632	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ANXA1—esophageal cancer	0.000483	0.000624	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—EGFR—esophageal cancer	0.00048	0.000621	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—WIF1—esophageal cancer	0.00048	0.00062	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GNG7—esophageal cancer	0.000475	0.000615	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—CXCL2—esophageal cancer	0.000472	0.00061	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—SST—esophageal cancer	0.00047	0.000607	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—CXCL2—esophageal cancer	0.000461	0.000596	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000459	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—WWOX—esophageal cancer	0.000458	0.000593	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—GHRL—esophageal cancer	0.000458	0.000592	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CSNK1A1—esophageal cancer	0.000443	0.000572	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ANXA1—esophageal cancer	0.000438	0.000567	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—NOS3—esophageal cancer	0.000437	0.000566	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FKBP1A—esophageal cancer	0.000436	0.000564	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ANXA1—esophageal cancer	0.000429	0.000555	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC52A3—esophageal cancer	0.000427	0.000552	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—BLVRB—esophageal cancer	0.000427	0.000552	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—SST—esophageal cancer	0.000426	0.000552	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—WIF1—esophageal cancer	0.000426	0.000551	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.00042	0.000543	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—CXCL2—esophageal cancer	0.000419	0.000542	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—SST—esophageal cancer	0.000417	0.000539	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000417	0.000539	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—GHRL—esophageal cancer	0.000416	0.000537	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PFN1—esophageal cancer	0.000414	0.000535	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB2—esophageal cancer	0.000409	0.000529	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000409	0.000529	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000407	0.000527	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—GHRL—esophageal cancer	0.000407	0.000526	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CSNK1A1—esophageal cancer	0.000393	0.000508	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ANXA1—esophageal cancer	0.000389	0.000504	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—SST—esophageal cancer	0.000379	0.00049	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—esophageal cancer	0.000373	0.000482	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ELMO1—esophageal cancer	0.000372	0.000481	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—GHRL—esophageal cancer	0.000369	0.000477	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PFN1—esophageal cancer	0.000368	0.000476	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000364	0.000471	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKAP13—esophageal cancer	0.000363	0.00047	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC10A2—esophageal cancer	0.000363	0.000469	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CA1—esophageal cancer	0.000363	0.000469	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000362	0.000469	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—PIK3CA—esophageal cancer	0.000362	0.000468	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCND1—esophageal cancer	0.000361	0.000467	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CDKN1A—esophageal cancer	0.00035	0.000452	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000335	0.000434	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EP300—esophageal cancer	0.000333	0.00043	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PDE4D—esophageal cancer	0.000332	0.00043	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CA2—esophageal cancer	0.000332	0.000429	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ELMO1—esophageal cancer	0.00033	0.000427	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—esophageal cancer	0.000324	0.000418	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKAP13—esophageal cancer	0.000323	0.000417	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GNG7—esophageal cancer	0.000316	0.000409	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADH7—esophageal cancer	0.000308	0.000399	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PLCE1—esophageal cancer	0.000308	0.000399	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000298	0.000385	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—XIAP—esophageal cancer	0.000296	0.000383	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PDE4D—esophageal cancer	0.000295	0.000382	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MYC—esophageal cancer	0.00029	0.000375	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—EGFR—esophageal cancer	0.000284	0.000367	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GNG7—esophageal cancer	0.000281	0.000363	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CTNNA1—esophageal cancer	0.00028	0.000362	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CXCL2—esophageal cancer	0.000279	0.00036	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ADH1B—esophageal cancer	0.00027	0.00035	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—XIAP—esophageal cancer	0.000263	0.00034	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PSME1—esophageal cancer	0.00026	0.000337	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PSME2—esophageal cancer	0.00026	0.000337	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ANXA1—esophageal cancer	0.000259	0.000335	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TYMP—esophageal cancer	0.000258	0.000334	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SST—esophageal cancer	0.000252	0.000326	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	0.000251	0.000325	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CTNNA1—esophageal cancer	0.000249	0.000322	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CXCL2—esophageal cancer	0.000247	0.00032	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CA—esophageal cancer	0.000246	0.000318	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOTCH3—esophageal cancer	0.000246	0.000317	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GHRL—esophageal cancer	0.000246	0.000317	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALOX15—esophageal cancer	0.000245	0.000317	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FBXW7—esophageal cancer	0.000242	0.000312	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—esophageal cancer	0.000238	0.000308	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTO1—esophageal cancer	0.000234	0.000302	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—TPI1—esophageal cancer	0.000234	0.000302	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PSME1—esophageal cancer	0.000231	0.000299	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PSME2—esophageal cancer	0.000231	0.000299	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ANXA1—esophageal cancer	0.00023	0.000297	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALDOB—esophageal cancer	0.000224	0.00029	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SST—esophageal cancer	0.000224	0.000289	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOTCH2—esophageal cancer	0.00022	0.000285	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOTCH3—esophageal cancer	0.000218	0.000282	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GHRL—esophageal cancer	0.000218	0.000282	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GAPDH—esophageal cancer	0.000216	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FBXW7—esophageal cancer	0.000215	0.000277	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CRABP1—esophageal cancer	0.000214	0.000276	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GNG7—esophageal cancer	0.000203	0.000263	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOTCH2—esophageal cancer	0.000196	0.000253	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TGFBR2—esophageal cancer	0.000195	0.000253	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALDH2—esophageal cancer	0.000191	0.000246	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SMAD4—esophageal cancer	0.000185	0.000239	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTT1—esophageal cancer	0.000181	0.000234	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	0.000179	0.000232	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TGFBR2—esophageal cancer	0.000174	0.000224	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS1—esophageal cancer	0.00017	0.00022	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ENO1—esophageal cancer	0.00017	0.00022	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PSME2—esophageal cancer	0.000167	0.000216	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PSME1—esophageal cancer	0.000167	0.000216	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SMAD4—esophageal cancer	0.000164	0.000212	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HIF1A—esophageal cancer	0.000151	0.000196	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KDR—esophageal cancer	0.000145	0.000187	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	0.000144	0.000187	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOTCH1—esophageal cancer	0.000136	0.000176	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	0.000136	0.000176	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HIF1A—esophageal cancer	0.000134	0.000174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KDR—esophageal cancer	0.000129	0.000166	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—HMOX1—esophageal cancer	0.000124	0.00016	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CREBBP—esophageal cancer	0.000124	0.00016	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—EGFR—esophageal cancer	0.000121	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOTCH1—esophageal cancer	0.000121	0.000157	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—esophageal cancer	0.000119	0.000154	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000116	0.00015	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—NOS3—esophageal cancer	0.000111	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CREBBP—esophageal cancer	0.00011	0.000142	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—EGFR—esophageal cancer	0.000108	0.000139	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CA—esophageal cancer	0.000105	0.000136	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB2—esophageal cancer	0.000103	0.000134	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000103	0.000133	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—NOS3—esophageal cancer	9.83e-05	0.000127	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CA—esophageal cancer	9.36e-05	0.000121	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB2—esophageal cancer	9.19e-05	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—esophageal cancer	9.14e-05	0.000118	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1A—esophageal cancer	8.85e-05	0.000114	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EP300—esophageal cancer	8.42e-05	0.000109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—esophageal cancer	8.12e-05	0.000105	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CREBBP—esophageal cancer	7.95e-05	0.000103	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1A—esophageal cancer	7.86e-05	0.000102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EP300—esophageal cancer	7.48e-05	9.67e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—esophageal cancer	7.33e-05	9.48e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EGFR—esophageal cancer	7.17e-05	9.28e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—NOS3—esophageal cancer	7.12e-05	9.2e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—esophageal cancer	6.51e-05	8.42e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.51e-05	8.42e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EGFR—esophageal cancer	6.37e-05	8.24e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CA—esophageal cancer	6.23e-05	8.05e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—esophageal cancer	6.02e-05	7.79e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CA—esophageal cancer	5.53e-05	7.15e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—EP300—esophageal cancer	5.41e-05	7e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—esophageal cancer	5.35e-05	6.92e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4e-05	5.18e-05	CbGpPWpGaD
